Are clinical trials in coronary heart disease oversold or undersold?
Randomized clinical trials constitute the formal experiments in therapeutics. Many such trials in coronary heart disease have terminated inconclusively or in controversy. In this editorial, we analyze some of the methodologic issues that may lead to controversy; the main reason for the low success rate may lie in insufficient understanding of the complex biology of the disease and in failure to select the appropriate models for therapy. We argue that these difficulties only strengthen the need for the rigorous experimental approach to the evaluation of therapies for coronary heart disease.